Recently added articles from Formulary:
Pipeline preview
May 01, 2009; ... Complete response * Budesonide/formoterol (Symbicort, AstraZeneca) for the long-term maintenance treatment of asthma in patients aged 6 to 11 years * Ecallantide (DX-88, Dyax) for the treatment of acute attacks of hereditary angioedema Recommended for approval * ...
New molecular entity
May 01, 2009; ... Afinitor Everolimus NOVARTIS Antineoplastic agent approved for the treatment of advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib Everolimus is an antineoplastic agent that inhibits mammalian target of rapamycin (mTOR), thus ...
New indication
May 01, 2009; ... Tygacil Tigecycline WYETH Tetracycline-class antibiotic approved for the treatment of community-acquired bacterial pneumonia Tigecycline is a glycylcycline antibiotic that exerts its antibacterial effects by inhibiting protein translation in bacteria. Tigecycline ...
actions in brief
May 01, 2009; ... FDA Artemether 20 mg/lumefantrine 120 mg (Coartem, Novartis) was approved for the treatment of acute uncomplicated infections due to Plasmodium falciparum. A vaccine (Ixiaro, lntercell) was approved for active immunization against viral infections of Japanese ...
Liraglutide: A human GLP-1 analogue for the treatment of type 2 diabetes
May 01, 2009; ... Abstract Liraglutide is the second glucagon-like peptide-1 (GLP-1) analogue in its class being considered for the treatment of type 2 diabetes mellitus. Liraglutide causes glucose-dependent increased insulin secretion, delayed glucagon secretion, and reduced appetite and gastric ...